E-nitiate Biopharmaceuticals (Hangzhou) Co.
Latest round
- Series B
Last raised
- Sep 2025
Total raised
- $43M
Investors
- 8
About E-nitiate Biopharmaceuticals (Hangzhou) Co.
,Ltd operates as an autoimmune disease drug developer. The company was established by VivaVision Biotech and Betta Pharmaceuticals fund. Betta Pharmaceuticals has become the strategic partner of the company in December 2020. More than 70% employees of the core research team has master's or doctor's degree. Wang Shen is the CTO of the company, he is the founder of Weimou biology and inventor of Lifitegrast. Shizhe Ding is the CEO of the company, he is the co-founder of Bega Capital, and once served as the director of strategic cooperation of Beida pharmaceutical and executive deputy general manager of Beida dream factory. The business of company includes R & D of innovative drugs for dermatology and immune diseases. The company's products include QY201 and QY101. QY201 can apply in psoriasis (moderate to severe), atopic dermatitis and alopecia areata. The company will submit for IND applications about QY211 and QY301.
Who invested in E-nitiate Biopharmaceuticals (Hangzhou) Co.
8 investors across 3 rounds
See all investors in E-nitiate Biopharmaceuticals (Hangzhou) Co.
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about E-nitiate Biopharmaceuticals (Hangzhou) Co.
Who invested in E-nitiate Biopharmaceuticals (Hangzhou) Co.?
E-nitiate Biopharmaceuticals (Hangzhou) Co. has 8 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has E-nitiate Biopharmaceuticals (Hangzhou) Co. raised?
E-nitiate Biopharmaceuticals (Hangzhou) Co. has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did E-nitiate Biopharmaceuticals (Hangzhou) Co. last raise money?
E-nitiate Biopharmaceuticals (Hangzhou) Co.'s most recent round on record is a Series B, in Sep 2025.
What does E-nitiate Biopharmaceuticals (Hangzhou) Co. do?
,Ltd operates as an autoimmune disease drug developer.
Where is E-nitiate Biopharmaceuticals (Hangzhou) Co. headquartered?
E-nitiate Biopharmaceuticals (Hangzhou) Co. is headquartered in Hangzhou, China.
Which VCs invest in companies like E-nitiate Biopharmaceuticals (Hangzhou) Co.?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Yufu Capital, ICBC Capital Management and Ningbo Tongshang Fund back biotechnology companies at E-nitiate Biopharmaceuticals (Hangzhou) Co.'s stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like E-nitiate Biopharmaceuticals (Hangzhou) Co.? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.